RxDoctor Payments DataLook up a doctor →

Gary Boone, MD

Adult Medicine · San Diego, CANPI 1073543781

Payments from drug & device makers

$4,891,766in general payments, 2019–2025

Across 687 payments — averaging $7120.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$4M
  • Pfizer$665K
  • AbbVie$265K
  • Amgen$3K
  • Eli Lilly$626
  • Seqirus USA Inc$102
  • plus $295 from 10 others
$2,495in research payments, 2019–2025

Across 3 payments — averaging $831.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi Pasteur Inc.$1K
  • Eli Lilly$1K

What the payments were for

  • Food & beverage$505100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,891,766 in reported general payments places this provider in the 95th percentile of 221 adult medicine providers in California.

See all adult medicine providers in California

Medicare billing

Part B allowed, 2024
$39,455
Medicare patients
98
Services billed
519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban40$40,501
FarxigaDapagliflozin Propanediol37$38,265
OzempicSemaglutide20$17,641
JardianceEmpagliflozin17$15,781
Repatha SureclickEvolocumab12$7,685
Humalog Kwikpen U-100Insulin Lispro16$6,128
Celecoxib71$3,912
Wixela InhubFluticasone Propion/Salmeterol18$2,791
Losartan Potassium158$1,940
Rosuvastatin Calcium53$1,815
Ezetimibe28$1,620
Tamsulosin Hcl77$1,486
Atorvastatin Calcium127$1,362
Metoprolol Succinate59$1,283
Oxycodone Hcl42$1,192

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$665,104$40,50140 claims
AstraZenecaFarxiga$24$38,26537 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 221 adult medicine providers in California.

Other adult medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →